As the Chief Medical Officer, and he works closely with pharmaceutical sponsors, with clinical investigators, and with Primera colleagues to ensure successful design, implementation, and completion of clinical research trials.
Dr. Spearman obtained his Ph.D. in Pharmacology and Toxicology from The University of Florida College of Medicine, and completed additional training at The University of Texas Southwestern Medical Center in Dallas and a National Cancer Institute Fellowship. His over 30 years of pharmaceutical experience includes efforts in all phases of product research (from preclinical through Phases 1, 2, and 3), clinical operations, clinical development, and medical affairs. These include preclinical and Phase 1 clinical research at Lilly Research Laboratories (Eli Lilly and Company), all parts of clinical operations and medical operations at Novartis Pharmaceuticals, clinical development and medical affairs at Amgen, and clinical development and the role of Gastroenterology Medical Director at UCB Pharma.
Dr. Spearman has published extensively throughout his career, including over 60 abstracts, peer-reviewed manuscripts, and book chapters. He also co-authored a patent for a drug that was approved for human use.